GGHC
CRNX icon

Gilder Gagnon Howe & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,470
Closed -$821K – 243
2025
Q1 		$821K Sell
24,470
-574
-2% -$21.4K 0.01% 191
2024
Q4 		$1.28M Buy
25,044
+12,429
+99% +$695K 0.01% 199
2024
Q3 		$645K Sell
12,615
-221
-2% -$11.4K 0.01% 223
2024
Q2 		$575K Buy
+12,836
New +$593K 0.01% 224

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's CRNX Position: Q2 2025 in Review

Gilder Gagnon Howe & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 24,470 shares — an estimated $821K sold.

Gilder Gagnon Howe & Co first reported a position in CRNX in Q2 2024 and held it in 4 quarters. The position peaked at $1.28M in Q4 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Gilder Gagnon Howe & Co reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 24,470 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $821K.
  • Gilder Gagnon Howe & Co first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Crinetics Pharmaceuticals position peaked at $1.28M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2025, filed 14 Aug 2025.